Background Rapid and sensitive tests for detecting buprenorphine and its metabolites for drug-screening situations have been long awaited. From the tests available, we have evaluated two on-site drugs-of-abuse testing devices using competitive binding immunoassays and one homogeneous enzyme immunoassay measured on an automated analyser.
Introduction
The drug buprenorphine has been shown to be e¡ective in reducing the signs and symptoms of opioid withdrawal, retaining patients in withdrawal treatment and supporting the completion of treatment regimens. 1 An essential part of maintenance therapy is the regular performance of urine drug screens on those undergoing therapy.When the use of buprenorphine became legal its illicit consumption also increased quickly due to its increased availability and to its relatively low price. 2 This increased use of buprenorphine has increased the need for buprenorphine testing. Although con¢rmation methods, such as gas or liquid chromatography (GC, LC) combined with mass spectrometry (MS), are needed for the speci¢c detec-tion of buprenorphine and its metabolites, a rapid and sensitive assay is of value for screening individuals and for drug monitoring. There are several immunological screening methods and devices for testing of common drugs of abuse. However, buprenorphine is rarely included in their repertoire.
In the present study, we have evaluated three commercially available immunological tests for detecting buprenorphine in urine, two of which are designed for use at the point-of-care. LC/MS was used as the con¢rmatory method against which the immunological tests were compared and from which the sensitivity and spe-ci¢city were calculated. In addition, special attention was paid to the operational characteristics of the point-of-care-based devices, with respect to the manual interpretation of the test result.
Materials and methods
Urine specimens (n ¼ 49) were stored at þ 41C up to one week or for longer periods of time at À201C. The pH of all urine specimens was between 6 and 7. The testing of the point-of-care devices was performed independently by two persons from the laboratory sta¡. The automated assay for buprenorphine testing was already in routine use in the laboratory.
The CEDIA s BuprenorphineAssay (Microgenics GmbH, Germany) 3, 4 was used on a Modular P800 instrument (Roche Diagnostics, Germany) utilizing the semiquantitative method application of the reagent manufacturer. The minimum detectable concentration of buprenorphine and buprenorphine-3-b-D-glucuronide was 1.25 ng/mL and the cut-o¡ value was 5 ng/mL. Norbuprenorphine and norbuprenorphine-3-b-D-glucuronide show no cross-reactivity at concentrations up to 1000 ng/mL.
Both the QuikPac II OneStep Buprenorphine cassette and the QuikStrip OneStep Buprenorphine strip tests (Syntron Bioresearch Inc., USA) consist of an immunochromatographic absorbent device where buprenorphine or its metabolites compete with a drug conjugate immobilized on a porous membrane for limited anti-body sites.When the drug in the specimen is at or above the detection limit it prevents the formation of a coloured band. Correspondingly, when the drug in the specimen is below the detection limit, the antibody-dye conjugate is free to bind the immobilized drug in the test zone, producing a coloured band. Furthermore, the dye conjugate binds to the reagent in the control zone, producing a coloured band. This acts as a control to ensure that the device is functioning properly.
In the QuikPac II assay, four drops of urine were added to the sample well in the cassette and the result was read after 5 min according to the kit instructions. Interpreting the results up to 10 min was acceptable. In the QuikStrip assay, the test strip was dipped in the urine for 30 s and the result was read after 5 and 30 min.The manufacturer recommends reading after 5 min but states that interpretation is valid for up to 30 min. In both of these tests the cut-o¡ for buprenorphine is 10 ng/mL and for buprenorphine-3-b-D-glucuronide is 2.5 ng/mL, respectively. The manufacturers state that norbuprenorphine and norbuprenorphine-3-b-D-glucuronide tested at concentrations up to 30,000 ng/mL show no cross-reactivity.
The con¢rmation analyses were performed by LC--electro spray (ES)--MS (Thermo Finnigan, San Jose, CA, USA). The limit for positive test result is 2 ng/mL for both buprenorphine and norbuprenorphine. The analytical e⁄ciency of the immunological assays is reported as sensitivity and speci¢city. 5 The calculation of these parameters was based on the following de¢nitions: 
Results and discussion
Altogether, 49 samples were tested from which 29 were con¢rmed to be positive by LC/ES/MS. Non-concordance of test results among the methods were obtained from eight samples and these are shown in Table 1 . The sensitivities and speci¢cities of the three screening tests are shown in Table 2 . The sensitivities ranged from 88% to100%. For the QuikStrip, when the reading was taken at 5 min, the sensitivity was 97%. However, when the reading was taken at 30 min, this fell to 88%. Correspondingly, the number of false-negative results increased from 1 to 4. For the QuikPac, no di¡erences were observed between results that were interpreted at either 5 or 10 min.
For all three kits, the speci¢cities obtained were between 91% and 100%. Two false-positive results were observed with the QuikPac (readings taken at 5 and 10 min) and with the QuikStrip (reading taken at 5 min).With the CEDIA s assay we also found one positive result ($13 ng/mL), which was negative for buprenorphine but positive for norbuprenorphine (60 ng/mL) by the con¢rmation test. This concentration of norbuprenorphine was, however, much lower than the reported detection limit (1000 ng/mL) of the CEDIA s assay.
We also observed that two samples with very high buprenorphine concentrations were not detected using the QuikStrip kit. In one specimen the concentrations of both buprenorphine and norbuprenorphine were above 100 ng/mL but the QuikStrip kit gave a negative result both after 5 and 30 min reading. In the other specimen, also with drug concentrations above 100 ng/mL, the QuikStrip kit gave a positive result when read after 5 min but a negative one when read after 30 min. We have observed similar ¢ndings when testing for amphetamines and cannabinoids, in that the point-of-care devices failed to detect the presence of drugs in samples with high drug concentrations. 6 In spite of the limited data presented here, our results indicate that depending on when the result is read, the point-of-care devices could give di¡erent test results. With the QuikStrip, increasing the reading time of test results up to 30 min led to an increased number of false-negative results (sensitivity 88%). There were ¢ve specimens positive at 5 min that turned negative at 30 min. Of these, three specimens were true positives. This ¢nding suggests that the QuikStrip assay is unreliable when read at 30 min. In contrast, identical results were obtained with the QuikPac assay whether the results were read at 5 or 10 min. Since we completed this study, versions of the QuikPac assay have become available that allow readings to be taken at 30 min. However, we have not evaluated these.
In conclusion, the results of this small study have shown that the CEDIA s Buprenorphine Assay performed in the laboratory performs better than either of the pointof-care tests. Furthermore, it has also demonstrated that any new point-of-care test should be properly evaluated by laboratory professionals before being put into routine use. It has also illustrated the need to have a reliable conformation test available, such as LC/ES/MS, in those instances where the result has legal implications.
